Back to Search Start Over

Rapidly Correcting Frameshift Mutations in the Mycobacterium tuberculosis orn Gene Produce Reversible Ethambutol Resistance and Small-Colony-Variant Morphology

Authors :
Subramanya Lingaraju
Seema Husain
David R. Sherman
Shuyi Ma
David Alland
Tige R. Rustad
Hassan Safi
Mainul Hoque
Patricia Soteropoulos
Source :
Antimicrobial Agents and Chemotherapy. 64
Publication Year :
2020
Publisher :
American Society for Microbiology, 2020.

Abstract

We have identified a previously unknown mechanism of reversible high-level ethambutol (EMB) resistance in Mycobacterium tuberculosis that is caused by a reversible frameshift mutation in the M. tuberculosis orn gene. A frameshift mutation in orn produces the small-colony-variant (SCV) phenotype, but this mutation does not change the MICs of any drug for wild-type M. tuberculosis However, the same orn mutation in a low-level EMB-resistant double embB-aftA mutant (MIC = 8 μg/ml) produces an SCV with an EMB MIC of 32 μg/ml. Reversible resistance is indistinguishable from a drug-persistent phenotype, because further culture of these orn-embB-aftA SCV mutants results in rapid reversion of the orn frameshifts, reestablishing the correct orn open reading frame, returning the culture to normal colony size, and reversing the EMB MIC back to that (8 μg/ml) of the parental strain. Transcriptomic analysis of orn-embB-aftA mutants compared to wild-type M. tuberculosis identified a 27-fold relative increase in the expression of embC, which is a cellular target for EMB. Expression of embC in orn-embB-aftA mutants was also increased 5-fold compared to that in the parental embB-aftA mutant, whereas large-colony orn frameshift revertants of the orn-embB-aftA mutant had levels of embC expression similar to that of the parental embB-aftA strain. Reversible frameshift mutants may contribute to a reversible form of microbiological drug resistance in human tuberculosis.

Details

ISSN :
10986596 and 00664804
Volume :
64
Database :
OpenAIRE
Journal :
Antimicrobial Agents and Chemotherapy
Accession number :
edsair.doi...........9325c7b8ecdbcfafe154bd98141d0d51
Full Text :
https://doi.org/10.1128/aac.00213-20